Highest-materiality recent filing
Raphael Pharmaceutical ready to launch RaphaWell RA supplement in US after clinical trial
RaphaWell is a 100% natural, plant-based dietary supplement for rheumatoid arthritis symptom management.
Raphael Pharma reports positive proof-of-concept study of cannabinoid formula in RA
DAS28 score reduced by 19.2%, moving from high to moderate disease activity in 12 patients.
Weinstein International CPA dismissed as independent auditor effective September 5, 2024.
Israeli Ministry of Health approved Raphael Pharmaceutical's application to commence a Phase IIa clinical trial in COVID-19 patients.
Raphael Pharma corrects CTO deal: $9k/month, 999k warrants at $0.01, royalty share
Service agreement with CTO Dr. Igal Louria Hayon corrected, monthly fee $9,000 through Dec 31, 2022.
Raphael Pharma dismisses Deloitte auditor, Chairman Press resigns; new exec comp agreements
Dismissed Brightman Almagor Zohar (Deloitte) as auditor; appointed Weinstein International as new independent auditor.
Mr. Ajay Kumar Dhadha voluntarily resigned from his positions as Chairman of the Board of Directors and Director of the Company, effective June 30, 2026.
Mr. Guy Ofir voluntarily resigned from his positions as Chief Financial Officer, General Counsel, and Director of the Company, effective July 16, 2026.
Effective July 16, 2026, the Company appointed Mr. Uri Tadelis as its Chief Financial Officer.
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
On June 30, 2022, Prof. Joseph Press informed the Company that he intended to resign from the Board of Directors, effective immediately.
Max materiality 0.70 · Median 0.55 · Most common event other_material